Advanced Enzyme Technologies Limited announces Financial Results for First Quarter ended June 2021 Advanced Enzyme Technologies Limited (Advanced Enzymes; NSE: ADVENZYMES; BSE: 540025), a leading specialty biotech company, with global leadership in the manufacturing of enzymes, today announced their unaudited financial results for first quarter ended June 2021. CONSOLIDATED FINANCIAL REVIEW (Y-o-Y basis): Revenue from Operations: Revenue from operations on consolidated basis increased to Rs 1,370 million in the Q1 FY22 from Rs 1,105 million in the Q1 FY21, showcasing a growth of 24%. Profit : Consolidated EBITDA during Q1 FY22 stands at Rs 628 million as compared to Rs 517 million during Q1 FY21, increase of 21%. Profit before tax stands at Rs 550 million during Q1 FY22 as against Rs 498 million in the previous year, a Y-o-Y growth of 10%. Profit after tax stands at Rs 399 million during Q1 FY22 as compared to Rs 348 million during the Q1 FY21, a growth of 15%. Margin EBITDA margin during Q1 FY22 stands at 46% as compared to 47% in Q1 FY21. PBT margin stands at 40% during Q1 FY22 as against 45% in the Q1 FY21. PAT margin stands at 29% during Q1 FY22 as against 31% in Q1 FY21. Financial Costs: Financial costs remained flat at Rs 5 million during the quarter. Depreciation and Amortization: Depreciation and Amortization charge for the Q1 FY22 is Rs 83 million as compared to Rs 67 million in the same quarter previous year. The increase is mainly on the account of SciTech Specialties Pvt. Ltd. (SSPL) consolidation in Q1 FY22 (SSPL was acquired on Jan 11, 2021). Earnings Per Share: Earnings Per Share during Q1 FY22 stands at Rs 3.40 as compared to Rs 3.13 in Q1 FY21. Result PDF